Engineers Gate Manager LP Altimmune, Inc. Transaction History

Engineers Gate Manager LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.4 - $3.45 $9,888 - $14,214	-4,120 Reduced 15.0%	23,355 $60,000
Q2 2023 Aug 14, 2023	BUY	$3.45 - $5.97 $94,788 - $164,025	27,475 New	27,475 $96,000
Q2 2022 Aug 15, 2022	SELL	$3.94 - $11.77 $56,598 - $169,076	-14,365 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.9 - $9.45 $84,753 - $135,749	14,365 New	14,365 $87,000
Q3 2021 Nov 15, 2021	SELL	$8.43 - $16.81 $117,421 - $234,146	-13,929 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.85 - $16.46 $10,963 - $18,319	1,113 Added 8.68%	13,929 $137,000
Q1 2021 May 17, 2021	SELL	$12.71 - $24.31 $164,353 - $314,352	-12,931 Reduced 50.22%	12,816 $181,000
Q4 2020 Feb 16, 2021	BUY	$7.84 - $14.22 $116,400 - $211,124	14,847 Added 136.21%	25,747 $290,000
Q3 2020 Nov 16, 2020	BUY	$9.93 - $33.26 $108,237 - $362,534	10,900 New	10,900 $144,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.